Post-approval studies (Phase 4)Ended earlyNCT04506086
What this trial is testing
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Who this might be right for
B-precursor Acute Lymphoblastic Leukemia
Amgen 10